publication date: Mar. 4, 2016

Doroshow: Evidence Suggests PDX Models Come Closer to Simulating Human Cancer


NCI is developing patient-derived xenograft mouse models as a potential substitute for the NCI-60 cell lines, a standard screen which experts say can no longer keep up with advances in cancer research and targeted molecular therapy.

“The goal is to try to understand whether these new models will be more successful in providing a better reflection of the underlying biology in the context of the clinical history and treatment history of patients from whence the tissues came,” said James Doroshow, director of the NCI Division of Cancer Treatment and Diagnosis and deputy director for clinical and translational research.

“We hope to be able to open the repository for distribution with somewhere between 50 and 100 xenografts in the first release. And we hope to have those available sometime early this summer.

“It will take, almost surely, at least one to two more years to have sufficient number of cell lines and then to do the validation and quality control studies in terms of drug sensitivity testing, to be even in the position to consider whether or not what was developed is ready to allow us to begin to phase out the NCI-60.”

Doroshow spoke with Matthew Ong, a reporter with The Cancer Letter.


Matthew Ong: There has been some talk about NCI’s plan to retire the NCI-60 cell lines and replace them with PDX models. What is NCI’s thinking on this?

Continue reading 42-09 Doroshow: Evidence Suggests PDX Models Come Closer to Simulating Human Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.